Online Registration is Open!
Register by Wednesday, December 3, 2014 in order to avoid paying the $100 onsite registration fee.
Printed from the IBC Life Sciences Web site on November 20, 2014 9:16 PM ET.
Page location: http://www.ibclifesciences.com/Vaccines/overview.xml
December 08-09, 2014 · Hilton Boston Back Bay · Boston, MA
Special Discounted Hotel Rate Available Until Friday, November 14, 2014. To book your room, call 617-236-1100 or toll free at 800-HILTONS (445-8667) and mention that you are an IBC attendee at this event.
December 10, 2014
Hilton Boston Back Bay · Boston, MA
IBC's co-located Environmental Monitoring & Contamination Control meeting covers the standards, regulations and guidelines for particle and environmental monitoring, clean manufacturing, filtration and air flow, and cleanroom design, considerations, testing and validation. Register today and learn how to:
IBC's Vaccine Development & Production Summit continues to bring you new data on ways to achieve your development and production goals. This year, hear the challenges and triumphs of product developers who continue to advance their innovations to combat emerging and infectious diseases.
From the development of new cell lines to novel formulation strategies to process design and manufacturing considerations, IBC's Vaccine Development & Production Summit gives you access to applicable knowledge that you can readily apply to your own vaccine development portfolio.
Immediately following IBC's Vaccine Development & Production Summit, ensure regulatory compliance in your cleanroom operations by attending IBC's Environmental Monitoring & Contamination Control meeting, taking place on December 10, 2014. Maximize your conference experience by attending both meetings!
Brochure Now Available
» Download Today!
Emerging Vaccine Markets and Their Potential
Chief General Manager
Indian Immunologicals Limited
Executive Director, Vaccine & Biologics Development
Characterization of Conjugate Vaccines from a Regulatory Perspective
Tina Roecklein, M.S.
Consumer Safety Officer, OVRR, DBPAP
CBER U.S. FDA
BARDA Core Services Enhancing Vaccine Development and Manufacturing
Arlene Joyner, MS, PMP
Senior Project Officer/Program Manager
Department of Health and Human Services/ASPR/OS/Biomedical Advanced Research and Development Authority (BARDA)
Learn how today's industry leaders are applying novel strategies and technologies to manufacturing vaccine therapeutics more efficiently while saving time and money
Discover how adjuvants are accelerating vaccine development efforts by gaining a comprehensive understanding on the role of adjuvants and the challenges faced by vaccinologists today during the creation of next generation vaccines
Hear a panel of experts discuss lessons learned from vaccines cold cases that continue to elude researchers, in addition to learning about impact that new technologies can have on conquering today's diseases and pandemics
Discover how flexible and microneedle patch products and technologies can potentially pave the way for painless self-vaccination
Exclusive Interview with Manon M.J. Cox, President and CEO, Protein Sciences Corporation
Protein Sciences Corporation developed the world's first recombinant, highly purified, egg-free influenza vaccine, Flublok®, which the FDA regards as a technological advance in the manufacturing of an influenza vaccine.
Listen to a 7 minute exclusive interview with Manon M.J. Cox.: